

Federica Cavallo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8161134/publications.pdf>

Version: 2024-02-01

185
papers

7,207
citations

76326

40
h-index

64796

79
g-index

185
all docs

185
docs citations

185
times ranked

8427
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and <i>anti-CSPG4</i> vaccination: A retrospective study on 68 cases (2010–2020). <i>Veterinary and Comparative Oncology</i> , 2022, 20, 189-197.	1.8	8
2	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	1.6	34
3	Role and Involvement of TENM4 and miR-708 in Breast Cancer Development and Therapy. <i>Cells</i> , 2022, 11, 172.	4.1	4
4	Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis. <i>Biomedicines</i> , 2022, 10, 230.	3.2	1
5	Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research. <i>Frontiers in Veterinary Science</i> , 2022, 9, 803093.	2.2	4
6	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	3.7	2
7	HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience. <i>Journal of Personalized Medicine</i> , 2022, 12, 285.	2.5	1
8	Are Cancer Stem Cells a Suitable Target for Breast Cancer Immunotherapy?. <i>Frontiers in Oncology</i> , 2022, 12, 877384.	2.8	4
9	Antigen mimicry as an effective strategy to induce <i>CSPG4</i> -targeted immunity in dogs with oral melanoma: a veterinary trial. , 2022, 10, e004007.		7
10	Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy. <i>OncImmunology</i> , 2022, 11, .	4.6	12
11	Role of Radiotherapy in Post-transplant Lymphoproliferative Disorders: Three Case Reports and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e309-e316.	0.4	3
12	Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential. <i>British Journal of Cancer</i> , 2021, 124, 207-216.	6.4	44
13	Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies. <i>Cells</i> , 2021, 10, 108.	4.1	16
14	Evaluation of prognostic impact of pre-treatment neutrophil to lymphocyte and lymphocyte to monocyte ratios in dogs with oral malignant melanoma treated with surgery and adjuvant <i>CSPG4</i> antigen electrovaccination: an explorative study. <i>Veterinary and Comparative Oncology</i> , 2021, 19, 353-361.	1.8	9
15	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 894.	3.7	6
16	The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 610303.	2.8	118
17	Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. <i>Journal of Personalized Medicine</i> , 2021, 11, 249.	2.5	6
18	Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant <i>CSPG4</i> DNA electrovaccination: A retrospective study on 155 cases. <i>Veterinary and Comparative Oncology</i> , 2021, 19, 651-660.	1.8	13

#	ARTICLE	IF	CITATIONS
19	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. <i>Hematological Oncology</i> , 2021, 39, 293-303.	1.7	6
20	MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. <i>Diagnostics</i> , 2021, 11, 779.	2.6	14
21	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	1.6	74
22	COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment. <i>HemaSphere</i> , 2021, 5, e592.	2.7	4
23	Targeting the Extracellular HSP90 Co-Chaperone Morgana Inhibits Cancer Cell Migration and Promotes Anticancer Immunity. <i>Cancer Research</i> , 2021, 81, 4794-4807.	0.9	16
24	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	5
25	The Amot/integrin protein complex transmits mechanical forces required for vascular expansion. <i>Cell Reports</i> , 2021, 36, 109616.	6.4	13
26	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. <i>MAbs</i> , 2021, 13, 1913791.	5.2	53
27	Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study. <i>Blood</i> , 2021, 138, 134-134.	1.4	3
28	Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 48-48.	1.4	2
29	Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	0
30	A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 2496-2496.	1.4	1
31	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
32	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020, 11, 37-40.	1.0	14
33	Breast cancer stem cell antigens as targets for immunotherapy. <i>Seminars in Immunology</i> , 2020, 47, 101386.	5.6	48
34	Cancer stem cell antigens as targets for new combined anti-cancer therapies. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 129, 105861.	2.8	12
35	Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2197-2199.	1.8	5
36	Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9418.	4.1	32

#	ARTICLE	IF	CITATIONS
37	Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. <i>Viruses</i> , 2020, 12, 488.	3.3	43
38	ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. <i>American Journal of Hematology</i> , 2020, 95, 1030-1037.	4.1	6
39	Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1039-1053.	3.4	26
40	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e511-e522.	4.6	201
41	Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 1492.	3.7	25
42	Droplet Digital PCR Assay for MYD88 ^{L265P} : Clinical Applications in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2020, 4, e324.	2.7	3
43	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. <i>Vaccines</i> , 2020, 8, 166.	4.4	1
44	Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study. <i>Blood</i> , 2020, 136, 1-2.	1.4	1
45	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2020, 136, 16-17.	1.4	2
46	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
47	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
48	Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial. <i>Blood</i> , 2020, 136, 29-30.	1.4	16
49	Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 131-141.	4.2	37
50	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , 2019, 134, 798-801.	1.4	53
51	A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S248-S249.	0.4	1
52	Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985549.	3.2	20
53	Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1839-1853.	4.2	34
54	Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 119-188.	1.7	32

#	ARTICLE	IF	CITATIONS
55	Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (<sc>FIL</sc>). <i>British Journal of Haematology</i> , 2019, 185, 713-717.	2.5	21
56	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019, 133, 919-926.	1.4	89
57	ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study. <i>Blood</i> , 2019, 134, 1565-1565.	1.4	1
58	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	1.3	11
59	A retrospective study of Râ€DHAP/Ox for early progressing follicular lymphoma. <i>British Journal of Haematology</i> , 2018, 183, 828-831.	2.5	3
60	Highly sensitive <i>MYD88</i> ^{L265P} mutation detection by droplet digital polymerase chain reaction in Waldenstrâ€m macroglobulinemia. <i>Haematologica</i> , 2018, 103, 1029-1037.	3.5	61
61	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term followâ€up. <i>British Journal of Haematology</i> , 2018, 181, 693-695.	2.5	1
62	A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer<i> in vivo</i>. <i>Oncolmmunology</i> , 2018, 7, e1408746.	4.6	49
63	Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells. <i>Oncolmmunology</i> , 2018, 7, e1494108.	4.6	26
64	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	6.2	22
65	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogsâ€™ Revolution for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 799.	4.1	33
66	Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 1417-1425.	3.4	25
67	Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2018, 132, 401-401.	1.4	7
68	Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenstrâ€m Macroglobulinemia Patients. <i>Blood</i> , 2018, 132, 1607-1607.	1.4	2
69	Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi. <i>Blood</i> , 2018, 132, 393-393.	1.4	26
70	Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. <i>Blood</i> , 2018, 132, 1677-1677.	1.4	2
71	NK cells control breast cancer and related cancer stem cell hematological spread. <i>Oncolmmunology</i> , 2017, 6, e1284718.	4.6	47
72	The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. <i>Nature Communications</i> , 2017, 8, 14797.	12.8	26

#	ARTICLE	IF	CITATIONS
73	The IKK/NF- κ B signaling pathway requires Morgana to drive breast cancer metastasis. <i>Nature Communications</i> , 2017, 8, 1636.	12.8	73
74	Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. <i>Vaccines</i> , 2017, 5, 20.	4.4	6
75	In vivo evaluation of tumour acidosis for assessing the early metabolic response and onset of resistance to dichloroacetate by using magnetic resonance pH imaging. <i>International Journal of Oncology</i> , 2017, 51, 498-506.	3.3	57
76	CSPG4: a prototype oncoantigen for translational immunotherapy studies. <i>Journal of Translational Medicine</i> , 2017, 15, 151.	4.4	51
77	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2016, 51, 1032-1040.	2.4	26
78	Protection of mice against the highly pathogenic VVHJD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity. <i>Antiviral Research</i> , 2016, 134, 182-191.	4.1	3
79	Preclinical pharmacokinetics comparison between resveratrol 2-hydroxypropyl- β -cyclodextrin complex and resveratrol suspension after oral administration. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2016, 86, 263-271.	1.6	12
80	Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging. <i>International Journal of Cancer</i> , 2016, 139, 404-413.	5.1	9
81	The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. <i>Oncolmmunology</i> , 2016, 5, e1253653.	4.6	30
82	Angiotenin like-1 is a novel component of the N-cadherin complex affecting endothelial/pericyte interaction in normal and tumor angiogenesis. <i>Scientific Reports</i> , 2016, 6, 30622.	3.3	22
83	A plant-expressed conjugate vaccine breaks CD4 ⁺ tolerance and induces potent immunity against metastatic Her2 ⁺ breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1166323.	4.6	36
84	Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer. <i>Cancer Research</i> , 2016, 76, 62-72.	0.9	93
85	Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2 ⁺ mammary cancer. <i>Oncolmmunology</i> , 2016, 5, e1082705.	4.6	9
86	The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2 ⁺ mammary cancer. <i>Plant Biotechnology Journal</i> , 2016, 14, 153-159.	8.3	12
87	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. <i>Blood</i> , 2016, 128, 3033-3033.	1.4	2
88	L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. <i>Oncotarget</i> , 2016, 7, 66713-66727.	1.8	54
89	A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model. <i>Oncotarget</i> , 2016, 7, 33081-33095.	1.8	15
90	Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohistochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP. <i>Blood</i> , 2016, 128, 5305-5305.	1.4	0

#	ARTICLE	IF	CITATIONS
91	The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3049-3049.	1.4	2
92	Novel insights into Notum and glypicans regulation in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 41237-41257.	1.8	50
93	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015, 3, 467-489.	4.4	38
94	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	4.6	119
95	Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment. <i>Magnetic Resonance Imaging</i> , 2015, 33, 725-736.	1.8	34
96	The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents. <i>Drugs</i> , 2015, 75, 367-375.	10.9	5
97	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. <i>Leukemia</i> , 2015, 29, 689-695.	7.2	75
98	Antitumor immunization of mothers delays tumor development in cancer-prone offspring. <i>Oncolmmunology</i> , 2015, 4, e1005500.	4.6	12
99	Efficacy of a Cancer Vaccine against <i>ALK</i> -Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1333-1343.	3.4	42
100	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3459-3466.	1.6	138
101	Management of Grade 3B Follicular Lymphoma (FL) Outside Clinical Trials: A Multicentric Retrospective Analysis on Behalf of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 2716-2716.	1.4	0
102	Outcome of Transformed FL(t-FL) Worsens According to the Timing of Transformation and to the Number of Previous Therapies. A Survey of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 3933-3933.	1.4	0
103	Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi. <i>Blood</i> , 2015, 126, 2686-2686.	1.4	12
104	De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC). <i>Blood</i> , 2015, 126, 2650-2650.	1.4	0
105	A Mathematical-Biological Joint Effort to Investigate the Tumor-Initiating Ability of Cancer Stem Cells. <i>PLoS ONE</i> , 2014, 9, e106193.	2.5	12
106	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	1.8	395
107	Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice. <i>BioMed Research International</i> , 2014, 2014, 1-16.	1.9	22
108	Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. <i>Journal of Immunology</i> , 2014, 192, 5434-5441.	0.8	16

#	ARTICLE	IF	CITATIONS
109	Xenogene vaccination in the therapy of cancer. Expert Opinion on Biological Therapy, 2014, 14, 1427-1442.	3.1	16
110	CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA. Clinical Cancer Research, 2014, 20, 3753-3762.	7.0	64
111	New Approaches to Management of Multiple Myeloma. Current Treatment Options in Oncology, 2014, 15, 157-170.	3.0	19
112	Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. Clinical Cancer Research, 2014, 20, 2910-2921.	7.0	24
113	MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. British Journal of Haematology, 2014, 164, 841-850.	2.5	20
114	Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. Current Topics in Microbiology and Immunology, 2014, 405, 99-122.	1.1	10
115	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. New England Journal of Medicine, 2014, 371, 895-905.	27.0	683
116	High-Risk Myeloma: When To Transplant Or Not. Seminars in Oncology, 2014, 41, e1-e9.	2.2	0
117	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study. Blood, 2014, 124, 175-175.	1.4	4
118	Superior Efficacy of VTD over VCD As Induction Therapy for Autotransplantation-Eligible, Newly Diagnosed, Myeloma Patients. Blood, 2014, 124, 197-197.	1.4	5
119	Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials. Blood, 2014, 124, 198-198.	1.4	3
120	Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis. Blood, 2014, 124, 2042-2042.	1.4	1
121	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. Journal of Clinical Oncology, 2014, 32, 8515-8515.	1.6	6
122	Role of Consolidation/Maintenance Therapy in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S349-S354.	0.4	7
123	Lenalidomide~prednisone induction followed by lenalidomide~melphalan~prednisone consolidation and lenalidomide~prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia, 2013, 27, 695-701.	7.2	31
124	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood, 2013, 122, 1376-1383.	1.4	74
125	Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives. Haematologica, 2013, 98, 660-661.	3.5	3
126	Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 2089-2089.	1.4	11

#	ARTICLE	IF	CITATIONS
127	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 536-536.	1.4	13
128	Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. <i>Blood</i> , 2013, 122, 539-539.	1.4	17
129	Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8509-8509.	1.6	15
130	Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors. <i>Blood</i> , 2013, 122, 2077-2077.	1.4	0
131	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 3126-3126.	1.4	2
132	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 933-939.	1.4	260
133	Have drug combinations supplanted stem cell transplantation in myeloma?. <i>Blood</i> , 2012, 120, 4692-4698.	1.4	33
134	Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1722-1727.	1.3	43
135	Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. <i>Future Oncology</i> , 2012, 8, 1223-1238.	2.4	11
136	Have drug combinations supplanted stem cell transplantation in myeloma?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 335-341.	2.5	5
137	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. <i>Blood</i> , 2012, 120, 2921-2921.	1.4	0
138	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. <i>Leukemia</i> , 2011, 25, 1627-1631.	7.2	51
139	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011, 117, 3025-3031.	1.4	247
140	A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. <i>Haematologica</i> , 2011, 96, 333-336.	3.5	52
141	Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. <i>Leukemia</i> , 2011, 25, 872-874.	7.2	56
142	Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study. <i>Blood</i> , 2011, 118, 3069-3069.	1.4	11
143	LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL. <i>Blood</i> , 2011, 118, 827-827.	1.4	6
144	Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010, 115, 1873-1879.	1.4	87

#	ARTICLE	IF	CITATIONS
145	Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2077-2084.	1.6	246
146	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. <i>Haematologica</i> , 2010, 95, 1144-1149.	3.5	40
147	A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen.. <i>Blood</i> , 2010, 116, 1092-1092.	1.4	17
148	A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 1940-1940.	1.4	5
149	Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat In Patients with Relapsed/Refractory MM: a Phase I-II Study. <i>Blood</i> , 2010, 116, 3019-3019.	1.4	5
150	A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m ² and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 3573-3573.	1.4	3
151	High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease. <i>Blood</i> , 2010, 116, 1898-1898.	1.4	0
152	Serum Free Light Chain Ratio, Total IgG Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. <i>Clinical Chemistry</i> , 2009, 55, 1510-1516.	3.2	33
153	New Combination Approaches for Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S42-S43.	1.4	0
154	A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200) Tj ETQq0 0 0 rgBT /Overlock 10 Analysis.. <i>Blood</i> , 2009, 114, 350-350.	1.4	11
155	Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.. <i>Blood</i> , 2009, 114, 960-960.	1.4	3
156	The Hemostatic System and Malignancy. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 230-236.	1.4	14
157	Lenalidomide and its role in the management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 865-874.	2.4	15
158	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008, 112, 3107-3114.	1.4	339
159	Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. <i>Haematologica</i> , 2008, 93, 953-954.	3.5	34
160	Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study. <i>Blood</i> , 2008, 112, 3683-3683.	1.4	11
161	A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2008, 112, 652-652.	1.4	33
162	Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 595-598.	1.0	25

#	ARTICLE	IF	CITATIONS
163	The treatment of the elderly multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 469-480.	1.3	4
164	Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. <i>Blood</i> , 2007, 109, 2767-2772.	1.4	174
165	Hyperammonemia and encephalopathy in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2007, 82, 414-415.	4.1	24
166	Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. <i>American Journal of Hematology</i> , 2007, 82, 831-833.	4.1	34
167	Time to first disease progression, but not β_2 -microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. <i>Cancer</i> , 2007, 110, 824-829.	4.1	19
168	Prospective Evaluation of the Bone Anabolic Effect of Bortezomib in Relapsed Multiple Myeloma (MM) Patients.. <i>Blood</i> , 2007, 110, 2719-2719.	1.4	3
169	Coagulation-Related Effect of Bortezomib Treatment in Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2733-2733.	1.4	1
170	A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m ² (Mel200) Versus Melphalan 100 mg/m ² (Mel100) in Newly Diagnosed Myeloma Patients.. <i>Blood</i> , 2007, 110, 727-727.	1.4	12
171	Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. <i>Blood</i> , 2006, 108, 1724-1732.	1.4	417
172	Intermediate-Dose Melphalan (100 mg/m ²)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 475-477.	1.4	22
173	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. <i>Leukemia Research</i> , 2006, 30, 283-285.	0.8	17
174	Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. <i>European Journal of Haematology</i> , 2006, 76, 273-277.	2.2	51
175	Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 449-453.	1.6	5
176	Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.. <i>Blood</i> , 2006, 108, 3100-3100.	1.4	0
177	Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. <i>Blood</i> , 2005, 105, 4784-4791.	1.4	80
178	Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. <i>European Journal of Haematology</i> , 2005, 75, 391-395.	2.2	36
179	Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3).. <i>Blood</i> , 2005, 106, 3490-3490.	1.4	23
180	Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. <i>The Hematology Journal</i> , 2004, 5, 318-324.	1.4	126

#	ARTICLE	IF	CITATIONS
181	Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma. <i>The Hematology Journal</i> , 2004, 5, 456-457.	1.4	11
182	Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m ²). <i>Leukemia</i> , 2004, 18, 133-138.	7.2	30
183	Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. <i>Blood</i> , 2004, 104, 3052-3057.	1.4	305
184	A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral Melphalan, Prednisone (MP): An Interim Analysis.. <i>Blood</i> , 2004, 104, 207-207.	1.4	24
185	PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 1398-1403.	1.6	35